T
TERNS PHARMACEUTICALS INC
NASDAQ: TERN (Terns Pharmaceuticals, Inc.)
Last update: 16 hours ago52.97
0.02 (0.04%)
| Previous Close | 52.95 |
| Open | 52.95 |
| Volume | 3,578,451 |
| Avg. Volume (3M) | 5,753,234 |
| Market Cap | 6,113,447,424 |
| Price / Sales | 302.64 |
| Price / Book | 6.08 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -1.08 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 30.89 |
| Operating Cash Flow (TTM) | -71.66 M |
| Levered Free Cash Flow (TTM) | -44.95 M |
| Return on Assets (TTM) | -22.15% |
| Return on Equity (TTM) | -32.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Terns Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.0 |
| Average | 1.25 |
|
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.28% |
| % Held by Institutions | 100.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capitolis Liquid Global Markets Llc | 31 Dec 2025 | 3,045,200 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |